Management of RhD-Negative or Unknown RhD Status
All pregnant patients should undergo RhD blood typing at the first prenatal visit, and RhD-negative unsensitized patients should receive Rh immune globulin (RhIG) at 28 weeks' gestation and again within 72 hours postpartum if the newborn is RhD-positive. 1
Initial Testing and Screening
Blood Type Determination
- Perform RhD typing on all pregnant patients at the first prenatal visit
- Include antibody screening to detect pre-existing alloimmunization
- If RhD status is unknown or uncertain, treat the patient as RhD-negative until proven otherwise 1
Special Consideration: Weak D Phenotype
When laboratory reports indicate a "serologic weak D phenotype":
- Request RHD genotyping to distinguish between weak D types and partial D phenotypes 2, 3
- Weak D types 1,2, or 3: Manage as RhD-positive (no RhIG needed)
- Partial D phenotypes: Manage as RhD-negative (RhIG required)
- If genotyping is unavailable or results are pending, default to treating as RhD-negative 1
RhIG Prophylaxis Protocol
Routine Antepartum Administration
At 28 weeks' gestation:
- Administer 300 mcg RhIG to all unsensitized RhD-negative patients
- This reduces alloimmunization risk from 1.8% to 0.1-0.2% 1, 4
Postpartum Administration
Within 72 hours of delivery:
- Confirm newborn's RhD status
- If newborn is RhD-positive or unknown: Administer 300 mcg RhIG
- Screen for excess fetomaternal hemorrhage (>15 mL fetal RBCs) using Kleihauer-Betke or flow cytometry
- Do NOT use rosette test if newborn has weak D phenotype (high false-negative rate) 2
- If >15 mL fetal blood detected: Calculate additional RhIG dose (10 mcg per mL fetal blood)
Sensitizing Events Requiring RhIG
Second and Third Trimester (≥12 weeks):
- Spontaneous or induced abortion
- Ectopic pregnancy
- Amniocentesis or chorionic villus sampling
- Cordocentesis
- External cephalic version
- Abdominal trauma
- Antepartum hemorrhage
- Intrauterine fetal death
- Dose: 300 mcg within 72 hours of event 1, 5
First Trimester (<12 weeks): This remains controversial with conflicting guidelines:
Society for Maternal-Fetal Medicine (2024) recommends: Offer both RhD testing and RhIG administration for spontaneous and induced abortion <12 weeks when logistically feasible 6
- Rationale: Fetal RBCs express D-antigen as early as 6 weeks; existing data insufficient to prove safety of withholding
- Risk of alloimmunization is low but not zero
- Prevention of future HDFN outweighs minimal risks of RhIG
Alternative approach (WHO, SFP): Forgo RhIG <12 weeks based on cost-effectiveness and very low risk
- French guidelines (2025) also recommend against routine first-trimester RhIG 7
Clinical recommendation: In settings where RhIG is accessible and does not impede care access, administer RhIG for first-trimester events given the severe consequences of HDFN and inadequate evidence proving safety of omission 6
Emerging Technology: Cell-Free Fetal DNA Testing
Consider cfDNA testing for fetal RhD genotype in select cases:
- Can identify RhD-negative fetuses in RhD-negative mothers (30-40% of cases)
- Allows avoidance of unnecessary RhIG administration
- Current limitations: Insufficient US population data, lack of standardization 8
- Most useful during RhIG shortage situations or in alloimmunized patients for monitoring decisions 8
Critical Pitfalls to Avoid
Never assume RhD-positive status without confirmation - if uncertain, give RhIG 1
Do not use rosette test for fetomaternal hemorrhage screening if newborn has weak D phenotype - use Kleihauer-Betke or flow cytometry instead 2
Do not perform unnecessary antiglobulin testing on maternal samples with negative immediate-spin reactions - this can lead to incorrect withholding of RhIG 2
Do not delay RhIG beyond 72 hours - efficacy decreases significantly after this window 1
Recognize that live virus vaccines (MMR, varicella) should be delayed 3 months after RhIG administration due to antibody interference 1
Document clearly: Use consistent terminology when reporting weak D phenotypes to avoid confusion 3
Special Populations
Trauma Patients Receiving O+ Blood Products
- RhD-negative females of childbearing age exposed to low-titer O+ whole blood have ~20% alloimmunization risk 9
- Calculate RBC volume transfused relative to total blood volume
- If <20% total blood volume: Administer RhIG
- If >20% total blood volume: RhIG insufficient; screen for anti-D antibodies at 6-12 months 10
Alloimmunized Pregnancies
Once alloimmunization has occurred, management shifts to fetal monitoring: